US FDA Delays Its Decision on Covid-19 Antibody Therapy of Roche/Regeneron
Just as the covid-19 antibody combination of Regeneron known as REGEN-COV has been sidelined in the United States because of the Omicron covid-19 variant, the drug is now facing another delay in getting the approval from the US FDA. The company said that, the Food and Drug Administration (FDA) of the United States has now […]
Continue Reading